casirivimab+imdevimab

DRUG5 trials

Sponsors

Regeneron Pharmaceuticals

Conditions

COVID-19Chronic Stable IllnessHealthyImmunocompromised

Phase 1

COVID-19 Study of Pharmacokinetics, Safety, Tolerability, and Efficacy of Intravenous Anti-Spike(s) SARS-CoV-2 Monoclonal Antibodies (Casirivimab+Imdevimab) for the Treatment of Pediatric Patients Hospitalized Due to COVID-19

TerminatedNCT05092581

Regeneron PharmaceuticalsCOVID-19

Start: 2021-12-16End: 2022-06-09Updated: 2025-10-14

COVID-19 Study Assessing the Safety and Tolerability of Co-Formulated Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies (Casirivimab+Imdevimab) in Adult Volunteers

CompletedNCT05181683

Regeneron PharmaceuticalsChronic Stable Illness, Healthy

Start: 2022-01-07End: 2022-06-03Updated: 2025-10-14

Phase 2

COVID-19 Study to Assess Immunogenicity, Safety, and Tolerability of Moderna mRNA-1273 Vaccine Administered With Casirivimab+Imdevimab in Healthy Adult Volunteers

CompletedNCT04852978

Regeneron PharmaceuticalsChronic Stable Illness, Healthy

Start: 2021-04-29End: 2022-11-21Updated: 2025-10-17

COVID-19 Administration of Single-Dose Subcutaneous Anti- Spike(s) SARS-CoV-2 Monoclonal Antibodies Casirivimab and Imdevimab in High-Risk Pediatric Participants Under 12 Years of Age

TerminatedNCT04992273

Regeneron PharmaceuticalsCOVID-19

Start: 2021-09-13End: 2022-06-01Updated: 2025-10-17

Phase 3

A Study to Evaluate Efficacy and Safety of Casirivimab+Imdevimab (Monoclonal Antibodies) for Prevention of COVID-19 in Immunocompromised Adolescents and Adults

TerminatedNCT05074433

Regeneron PharmaceuticalsImmunocompromised

Start: 2021-10-25End: 2022-05-18Updated: 2025-10-17

Related Papers

Effect of timing of casirivimab and imdevimab administration relative to mRNA-1273 COVID-19 vaccination on vaccine-induced SARS-CoV-2 neutralising antibody responses: a prospective, open-label, phase 2, randomised controlled trial.

2024-09-023 citations